Paige Announces New Data on Breast Cancer Detection System To Be Presented at San Antonio Breast Cancer Virtual Symposium December 8-11.

Awl-in-One Tap (Next-Generation) Granted U.S. Patent Reports EDGe Surgical

Awl-in-One Tap is a single-use spinal surgery instrument with disposable neuromonitoring EMG system and digital depth measurement built in. The device, which is under development, is intended to be used when creating a screw hole pathway during posterior pedicle spinal fusion surgeries.

Healthcare Safety Preparedness Post-Covid-19: Protection from Violence and Virus

If the nation has learned anything from the Covid-19 crisis, it’s that advance planning in safety preparedness is vital to our ability to respond to emergencies, whether they’re viral, violent, or otherwise.

December 7, 2020

Paige, is a global leader in AI-based digital diagnostics. Today the company announced they will present new data evaluating Paige Breast Alpha, a machine learning system designed to detect breast cancer in digital images of breast tissue, at the upcoming 2020 San Antonio Breast Cancer Symposium (SABCS 2020), taking place virtually December 8-11, 2020.

Paige notes for pathologists reviewing breast tissue slides under the microscope, the large volume of slides can pose significant challenges for workload management and pathologist productivity. The poster, “Clinical-grade detection of breast cancer in biopsies and excisions using machine learning,” will be featured during a spotlight poster discussion, which highlights some of the most noteworthy and groundbreaking research submitted to the conference.

The poster abstract is available online and viewing details are below:

  • Clinical-grade detection of breast cancer in biopsies and excisions using machine learning
    Authors: Hanna MG, et al.
    Session: Spotlight Poster Discussion 6 | Thursday, December 10, 2020 | 3:30pm – 4:45pm CST
    Poster #: PD6-03

Paige was founded in 2017 by Thomas Fuchs, Dr.Sc. and colleagues from Memorial Sloan Kettering Cancer Center (MSK). The company builds computational pathology products designed so patients and their care teams can make effective, more informed treatment decisions. With this new class of AI-based technologies positioned to drive the future of diagnostics, Paige created a platform to deliver this novel technology to pathologists to transform their workflow and increase diagnostidc confidence and productivity. Paige’s products deliver insights to pathologists and oncologists so they can arrive efficiently at more precise diagnoses for patients. Paige is the first company to receive FDA breakthrough designation for computational pathology products.

spot_img

DON'T MISS

Related Articles